⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL1450443 | 0.97 | — | — | |
| SCHEMBL2671352 | 0.94 | — | — | |
| SCHEMBL9498015 | 0.94 | — | — | |
| SCHEMBL10338084 | 0.94 | — | — | |
| SCHEMBL5367506 | 0.94 | CA4 (0.33) | — | |
| SCHEMBL9619101 | 0.94 | — | — | |
| Silver SCHEMBL3907380 | 0.94 | — | — | |
| Potassium Ion SCHEMBL3280844 | 0.94 | CA4 (0.33) | — | |
| SCHEMBL3907387 | 0.94 | — | — | |
| SCHEMBL30418339 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-25 | — | — | US | claimed |
| WO-2013006734-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2013-01-10 | — | — | WO | claimed |
| EP-0201804-B1 | COMPOSITION TO TREATING BONE DISORDERS | Sloan-Kettering Institute For Cancer Research (US) | 1992-07-01 | — | — | EP | claimed |
| US-4686104-A | GERMANIUM OR PLATINUM COMPOUNDS TO DECREASE CALCIUM LOSS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1987-08-11 | — | — | US | claimed |
| EP-0201804-A1 | Composition to treating bone disorders | Sloan-Kettering Institute For Cancer Research (US) | 1986-11-20 | — | — | EP | claimed |
| US-20240189409-A1 | Personalized Site-Specific Immunomodulation | QU BIOLOGICS INC. (CA) | 2024-06-13 | — | — | US | disclosed |
| EP-4324526-A2 | IMMUNOGENIC ANTI-INFLAMMATORY COMPOSITIONS | Qu Biologics Inc. (CA) | 2024-02-21 | — | — | EP | disclosed |
| US-11679111-B2 | Fatty acid synthase inhibitors | DUKE UNIVERSITY (US) | 2023-06-20 | — | — | US | disclosed |
| US-11642362-B2 | Methods of inhibiting cell proliferation and METTL8 activity | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-05-09 | — | — | US | disclosed |
| CN-109790191-B | Platinum complexes and methods of use thereof | 香港大学 | 2022-04-08 | — | — | CN | disclosed |
| US-20200222444-A1 | METHODS OF INHIBITING CELL PROLIFERATION AND METTL8 ACTIVITY | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2020-07-16 | — | — | US | disclosed |
| EP-3649242-A2 | METHODS OF INHIBITING CELL PROLIFERATION AND METTL8 ACTIVITY | National University of Singapore (SG) | 2020-05-13 | — | — | EP | disclosed |
| US-20060089341-A1 | Protein-bound derivatives of platinum complexes containing cyclobutane1,1-dicarboxyllate ligands | KTB TUMORFORSCHUNGS GMBH (DE) | 2006-04-27 | — | — | US | disclosed |
| US-20040258770-A1 | Use of 4-pyridylmethylphthalazines for cancer treatment | DUGAN MARGARET HAN (US) | 2004-12-23 | — | — | US | disclosed |
| US-20040258771-A1 | Reduced toxicity cisplatin formulations and methods for using the same | TOSK, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040235796-A1 | Combinations comprising epothilones and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2004-11-25 | — | — | US | disclosed |
| US-20030082102-A1 | Radioactive platinum complexes for cancer treatment | ORDER, STANLEY E., MD PC D/B/A CENTER FOR MOLECULAR MEDICINE | 2003-05-01 | — | — | US | disclosed |
| US-5877215-A | Method of treating neoplastic cells with prostaglandin and radiation treatment or prostaglandin and platinum-based anti-tumor agents | MEDICAL UNIVERSITY OF SOUTH CAROLINA (US) | 1999-03-02 | — | — | US | disclosed |
| US-5620703-A | LIPOSOME-ENCAPSULATED ANTITUMOR,-CARCINOGENIC AGENTS; VIRICIDES; LEUKOPENIA | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 1997-04-15 | — | — | US | disclosed |
| EP-0201804-B1 | COMPOSITION TO TREATING BONE DISORDERS | Sloan-Kettering Institute For Cancer Research (US) | 1992-07-01 | — | — | EP | disclosed |